Beigene LtdNASDAQ:BGNE
- LAST PRICE226.2900
- TODAY'S CHANGE (%)1.7800 (0.7928%)
- Bid / Lots225.6500/ 2
- Ask / Lots226.5200/ 2
- Open / Previous Close222.9600 / 224.5100
- Day Range
- 52 Week Range
- Volume143,416
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BGNE |
|---|---|---|
| 09:32 ET | 2000 | 222.165 |
| 09:34 ET | 150 | 222.34 |
| 09:36 ET | 239 | 223.94 |
| 09:38 ET | 4251 | 224.8 |
| 09:39 ET | 200 | 224.38 |
| 09:41 ET | 400 | 224.495 |
| 09:43 ET | 400 | 224.98 |
| 09:45 ET | 571 | 225.75 |
| 09:48 ET | 360 | 225.905 |
| 09:50 ET | 250 | 226.505 |
| 09:52 ET | 7820 | 225.075 |
| 09:54 ET | 810 | 224.77 |
| 09:56 ET | 100 | 224.57 |
| 09:57 ET | 4739 | 224.07 |
| 09:59 ET | 2643 | 223.91 |
| 10:01 ET | 100 | 223.77 |
| 10:03 ET | 1500 | 224.28 |
| 10:06 ET | 1045 | 223.55 |
| 10:08 ET | 213 | 223.485 |
| 10:10 ET | 800 | 224.07 |
| 10:12 ET | 914 | 223.06 |
| 10:14 ET | 100 | 222.75 |
| 10:15 ET | 109 | 222.97 |
| 10:17 ET | 263 | 222.54 |
| 10:19 ET | 2652 | 222.36 |
| 10:21 ET | 4783 | 221.95 |
| 10:24 ET | 1200 | 223.25 |
| 10:26 ET | 200 | 223.25 |
| 10:28 ET | 110 | 223.19 |
| 10:30 ET | 577 | 222.785 |
| 10:32 ET | 300 | 222.695 |
| 10:33 ET | 229 | 222.095 |
| 10:35 ET | 108 | 222.035 |
| 10:37 ET | 200 | 222.06 |
| 10:39 ET | 3542 | 223.37 |
| 10:42 ET | 401 | 223.48 |
| 10:46 ET | 100 | 223.525 |
| 10:50 ET | 800 | 222.58 |
| 10:51 ET | 100 | 221.61 |
| 10:53 ET | 200 | 221.17 |
| 10:55 ET | 1870 | 221.81 |
| 10:57 ET | 100 | 222.42 |
| 11:00 ET | 128 | 222 |
| 11:02 ET | 600 | 222.385 |
| 11:04 ET | 700 | 222.47 |
| 11:06 ET | 400 | 223.13 |
| 11:08 ET | 806 | 223.45 |
| 11:09 ET | 400 | 223.27 |
| 11:11 ET | 605 | 222.45 |
| 11:13 ET | 513 | 222.64 |
| 11:15 ET | 200 | 222.755 |
| 11:18 ET | 300 | 223.075 |
| 11:20 ET | 609 | 222.965 |
| 11:22 ET | 676 | 223.2 |
| 11:24 ET | 466 | 223.47 |
| 11:26 ET | 800 | 223.555 |
| 11:29 ET | 400 | 223.18 |
| 11:31 ET | 1800 | 224.42 |
| 11:33 ET | 1300 | 223.8 |
| 11:38 ET | 400 | 223.08 |
| 11:40 ET | 100 | 223.04 |
| 11:42 ET | 300 | 223 |
| 11:44 ET | 400 | 223.275 |
| 11:47 ET | 1570 | 224.165 |
| 11:49 ET | 284 | 224.15 |
| 11:51 ET | 409 | 224.165 |
| 11:54 ET | 200 | 224.42 |
| 11:56 ET | 2255 | 224.874 |
| 11:58 ET | 300 | 224.945 |
| 12:00 ET | 200 | 225.3 |
| 12:02 ET | 100 | 225.11 |
| 12:03 ET | 200 | 225.135 |
| 12:05 ET | 700 | 225.87 |
| 12:07 ET | 2306 | 226.02 |
| 12:09 ET | 1225 | 226.7 |
| 12:12 ET | 810 | 226.7 |
| 12:14 ET | 400 | 226.7 |
| 12:16 ET | 242 | 226.73 |
| 12:18 ET | 400 | 226.19 |
| 12:20 ET | 600 | 226.155 |
| 12:21 ET | 734 | 226.36 |
| 12:23 ET | 102 | 226.125 |
| 12:25 ET | 401 | 226.29 |
Sep 26, 2024
BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA(R), for Treatment of ESCC and Gastric/GEJ Cancers, from 6:21PM ET on Thursday Sep 26, 2024 by Dow Jones
6:21PM ET on Thursday Sep 26, 2024 by Dow JonesGlobal Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors, from 6:00AM ET on Thursday Sep 26, 2024 by Dow Jones
6:00AM ET on Thursday Sep 26, 2024 by Dow Jones*DJ BeiGene Appoints Shalini Sharp to Board of Directors, from 6:00AM ET on Thursday Sep 26, 2024 by Dow Jones
6:00AM ET on Thursday Sep 26, 2024 by Dow Jones
Sep 18, 2024
DJ BeiGene Initiated at Market Outperform by JMP Securities, from 5:52AM ET on Wednesday Sep 18, 2024 by Dow Jones
5:52AM ET on Wednesday Sep 18, 2024 by Dow Jones
Sep 17, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Beigene Ltd | 26.5B | -44.6x | --- |
United Therapeutics Corp | 15.9B | 16.4x | +8.22% |
Alnylam Pharmaceuticals Inc | 35.3B | -438.0x | --- |
Biomarin Pharmaceutical Inc | 13.4B | 53.2x | --- |
argenx SE | 32.4B | -157.3x | --- |
Exact Sciences Corp | 12.6B | -70.5x | --- |
Company Information
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.
Contact Information
- Headquarters
- C/O Mourant Governance Services (Cayman) 94 Solaris Avenue, Camana BayGRAND CAYMAN, BEJ, Cayman Islands KY1-1108
- Phone
- 345-949-4123
- Fax
- ---
Executives
- Co-Founder, Executive Chairman of the Board, Chief Executive Officer
- John Oyler
- President, Chief Operating Officer, General Manager - China
- Xiaobin Wu
- Co-Founder, Non-Executive Director
- Xiaodong Wang
- Chief Financial Officer
- Aaron Rosenberg
- General Manager, North America
- Matthew Shaulis
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $26.5B |
|---|---|
Revenue (TTM) | $3.1B |
Shares Outstanding | 106.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.62 |
EPS | $-5.08 |
Book Value | $36.95 |
P/E Ratio | -44.6x |
Price/Sales (TTM) | 8.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -16.90% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
